Table 3 of Gu, Mol Vis 2016; 22:646-657.


Table 3. Genetic and clinical features of all reported Chinese RP patients.

Mutation Patient ID Disease Age (year)/ Sex Onset Age (year) Clinical presentation Reference
Type Nucleotide Amino Acid BCVA Fundus ERG VF
O.D. O.S. Pigments Optic disc
1* - p.E1836* (Hom) II:1 RP NA/F 20 20/400 HM - - Diminished - [28]
1* - p.E1836* (Hom) II:2 RP 40/M 15 20/400 20/400 Diffuse Mild pallor Diminished - [28]
1* - p.E1836* (Hom) II:5 RP NA/F 20 20/400 HM - - Diminished - [28]
1* c.[8012T>A];[704G>A] p.[L2671*];[W235*] F35–1 IRDs 43/M 13 20/100 20/100 - - - - [29]
2# c.[490C>T];[6416G>A] p.[R614*];[C2139Y] ARRP05-II:3 RP 40/M 22 FC FC Diffuse Waxy Diminished - [24]
2# c.[490C>T];[6416G>A] p.[R614*];[C2139Y] ARRP05-II:5 RP 37/M 20 HM HM - - - - [24]
2# c.[490C>T];[6416G>A] p.[R614*];[C2139Y] ARRP05-II:7 RP 32/M 25 20/200 20/200 Diffuse Waxy Diminished - [24]
2# c.[7919G>A];[8861T>C] p.[W2640*];[F2954S] ARRP06-II:2 RP 54/M 18 LP LP Diffuse Waxy Diminished - [24]
2# c.[7919G>A];[8861T>C] p.[W2640*];[F2954S] ARRP06-II:4 RP 52/M 35 LP LP Diffuse Waxy Diminished - [24]
2# c.[7919G>A];[8861T>C] p.[W2640*];[F2954S] ARRP06-II:8 RP 49/F 32 20/25 20/25 Diffuse Waxy Reduced Constricted [24]
2# c.[6557G>A];
[9186_9187delCA] p.[G2186E];[NA] W127–1 IRDs 48/F 20 20/100 20/500 - - - - [29]
2# c.[6416G>A];[8150delA] p.[C2139Y];[NA] W286–1 IRDs 43/M 20 FC 20/400 - - - - [29]
2# c.[2510G>T];[8107G>T] p.[C837F];[E2703*] F11–1 IRDs 48/M 41 20/50 20/50 - - - - [29]
2# c.[7492G>C];
[8244_8245insT] p.[A2498P];[NA] W82–1 IRDs 43/F 22 20/40 20/40 - - - - [29]
2# c.[6416G>A];[8392delG] p.[C2139Y];[NA] W86–1 IRDs 25/M 15 20/32 20/32 - - - - [29]
3$ c.[6416G>A];[6557G>A] p.[C2139Y];[G2186E] No.10-II:1 RP 49/F 42 20/30 20/30 Diffuse Mild pallor Diminished Constricted [27]
3$ c.[6416G>A];[6557G>A] p.[C2139Y];[G2186E] No.10-II:3 RP 45/M 36 20/50 20/40 Diffuse Mild pallor Diminished Constricted [27]
3$ c.[6416G>A];[6557G>A] p.[C2139Y];[G2186E] No.10-II:4 RP 35/F 20 20/30 20/30 Diffuse Mild pallor Diminished Constricted [27]
3$ c.[9368A>C];[6416G>A] p.[N3123T];[C2139Y] W5–1 IRDs 34/M 14 20/40 20/40 - - - - [29]
3$ c.7492G>C (Hom) p.A2498P (Hom) W159–1 IRDs 34/M 20 20/40 20/50 - - - - [29]
3$ c.[7609G>A];[7949C>T] p.[A2537T];[S2650F] W171–1 IRDs 37/F 20 FC FC - - - - [29]
3$ c.[3489T>A];[2644T>C] p.[N1163K];[F882L] W13–1 IRDs 63/M 41 20/125 20/100 - - - - [29])
3$ c.6416G>A (Hom) p.C2139Y (Hom) W75–1 IRDs 31/M 20 20/100 20/100 - - - - [29]